A Phase 2 Randomized, Double-Blind, Crossover, Controlled, Multi-Center Subject Preference Study of Tivozanib Hydrochloride Versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma
Latest Information Update: 13 Jun 2022
At a glance
- Drugs Tivozanib (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms TAURUS
- Sponsors AVEO Oncology
- 06 Jun 2022 Results of subgroup analysis published in AVEO Oncology Media Release.
- 06 Jun 2022 According to an AVEO Oncology media release, data from subgroup analysis presented during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 05 Oct 2020 Status changed from completed to discontinued.